Patent: 6,524,570
✉ Email this page to a colleague
Summary for Patent: 6,524,570
Title: | Polyethylene glycol modified interferon therapy |
Abstract: | A method comprising administering a PEG.sub.12000 -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed. |
Inventor(s): | Glue; Paul (Flemington, NJ), Cutler; David L. (Morristown, NJ), Affrime; Melton B. (Flemington, NJ) |
Assignee: | Schering Corporation (Kanilworth, NJ) |
Application Number: | 09/699,663 |
Patent Claims: | see list of patent claims |
Details for Patent 6,524,570
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | PEGINTRON | peginterferon alfa-2b | Injection | 103949 | 01/19/2001 | ⤷ Try a Trial | 2015-11-02 |
Merck Sharp & Dohme Corp. | SYLATRON | peginterferon alfa-2b | For Injection | 103949 | 03/29/2011 | ⤷ Try a Trial | 2015-11-02 |
Hoffmann-la Roche Inc. | PEGASYS COPEGUS COMBINATION PACK | peginterferon alfa-2a and ribavirin | 125083 | 06/04/2004 | ⤷ Try a Trial | 2015-11-02 | |
Schering Corporation A Subsidiary Of Merck & Co., Inc. | PEGINTRON/ REBETOL COMBO PACK | peginterferon alfa-2b and ribavirin | 125196 | 06/13/2008 | ⤷ Try a Trial | 2015-11-02 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,524,570
Country | Patent Number | Estimated Expiration |
---|---|---|
Argentina | 012614 | ⤷ Try a Trial |
Austria | 255421 | ⤷ Try a Trial |
Austria | 262920 | ⤷ Try a Trial |
Australia | 7249098 | ⤷ Try a Trial |
Australia | 7473096 | ⤷ Try a Trial |
Brazil | 9809425 | ⤷ Try a Trial |
Canada | 2236591 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |